Full Press Release Details
InMed to Present at Canaccord Genuity's
5th Annual Global Cannabis Conference on May 11th, 2021
Vancouver, BC - May 4th,
2021 - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM; TSX:IN), a clinical-stage
company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol ("CBN"),
today announced that Eric. A. Adams, President and CEO of InMed, will be presenting at Canaccord Genuity's 5th Annual Global Cannabis
Conference on Tuesday, May 11th, which is being held virtually this year. Details on the conference and how to participate
Date: Tuesday, May 11th,
Presentation Details: Tuesday, May 11th at
Presentation Link: https://wsw.com/webcast/canaccord55/inm/2252448
Eric A. Adams and Bruce Colwill, InMed's
Chief Financial Officer, will also be conducting 1x1 meetings throughout the conference with institutional investor groups and family
offices. In order to schedule a meeting, please do so through the conference portal or reach out to info@inmedpharma.com. Information
on this event will also be posted on InMed's event page, which can be found at: www.inmedpharma.com/about/events.
About InMed: InMed Pharmaceuticals
is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic
benefits of cannabinol ("CBN"), in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic
alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.
Investor Contact: Edison Group
Joe Green/Laine Yonker
T: +1.646.653.7030/+1.646.653.7035
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to
a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
Forward-looking information in this news release includes statements about: presenting at Canaccord Genuity's 5th Annual Global
Cannabis Conference; leading the way in the clinical development of cannabinol (CBN); developing a pipeline of cannabinoid-based medications
in diseases with high unmet medical need; and delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based
All forward-looking information herein is qualified in its entirety
by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly
announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments,
except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES
PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.